Imiglimin 500 IR is an immediate-release oral tablet containing 500 mg of Imiglimin, a novel anti-diabetic agent designed to improve glycemic control in adults with type 2 diabetes mellitus. It works by enhancing insulin secretion from pancreatic beta cells, improving insulin sensitivity in peripheral tissues, and modulating hepatic glucose production. This dual-action mechanism helps maintain stable blood sugar levels throughout the day, reducing both fasting and postprandial hyperglycemia. Imiglimin 500 IR is suitable as monotherapy or in combination with other anti-diabetic medications. The immediate-release formulation ensures rapid absorption, providing effective glucose control with predictable pharmacokinetics.
